HOME > BUSINESS
BUSINESS
- Business Revamp “Just Getting Started”: Sumitomo Pharma CEO
August 19, 2024
- Tremfya Filed for Crohn’s Disease in Japan: J&J
August 13, 2024
- MSD Seeks Japan Nod for 21-Valent Pneumococcal Jab for Adults
August 13, 2024
- Opdivo-Yervoy Combo Filed for HCC in Japan
August 13, 2024
- Takeda Seeks CIDP Nod for Immunoglobulin Hyqvia in Japan
August 9, 2024
- Japan Patented Drug Market Breaks 7 Trillion Yen in FY2023: IQVIA
August 9, 2024
- Hizentra Now Available in Prefilled Syringe Form in Japan: CSL
August 9, 2024
- Nobelpharma to Launch Hypozincemia Drug Zintus on August 20
August 9, 2024
- Pfizer Earns Japan Nod for JN.1-Adapted COVID Vaccine
August 9, 2024
- Takeda’s Adzynma Approved in Europe, Launch Set for September
August 9, 2024
- Japan Ethical Drug Sales Down 5.5% in June: Crecon
August 9, 2024
- Daiichi, Merck Expand ADC Deal into Harpoon’s T-Cell Engager
August 8, 2024
- Chugai Gets Japan Rights to Roche’s Anti-TL1A IBD Drug
August 8, 2024
- Anapeine Restriction Forcing Sandoz to Curb Supply of More Local Anesthetics
August 7, 2024
- Sandoz to Discontinue Paxil AGs as Originator Pulls Out
August 7, 2024
- Kyorin, Jikei Startup Ink Option Deal for Respiratory Disease Treatment
August 7, 2024
- NCC Offshoot’s 1st CAR-T Therapy Set to Enter Clinic Next Year: CEO
August 7, 2024
- Santen Axes Diquas LX Outlook to Zero for Now as Supply Halt Continues
August 7, 2024
- Santen Snags Asian Rights to Cloudbreak’s Topical Pterygium Drug
August 7, 2024
- Keytruda Tops Japan Sales Ranking for 10th Straight Month: Encise
August 7, 2024
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…